TCE赛道产业爆发,应用边界不断延伸,技术持续迭代。在今年的ASH年会上,维立志博的条件性激活的GPRC5D/CD3双抗LBL-034,凭借颠覆多发性骨髓瘤治疗的潜力,入选ASH年会首场口头汇报的首个重磅议题。ASH大会上更新的数据进一步佐证了LBL-034的颠覆力:400μg/kg剂量组中位随访13.1个月仍表现惊艳,高剂量组响应快速、应答比例高、缓解深度足;400-1200μg/kg剂量组客观...
Source LinkTCE赛道产业爆发,应用边界不断延伸,技术持续迭代。在今年的ASH年会上,维立志博的条件性激活的GPRC5D/CD3双抗LBL-034,凭借颠覆多发性骨髓瘤治疗的潜力,入选ASH年会首场口头汇报的首个重磅议题。ASH大会上更新的数据进一步佐证了LBL-034的颠覆力:400μg/kg剂量组中位随访13.1个月仍表现惊艳,高剂量组响应快速、应答比例高、缓解深度足;400-1200μg/kg剂量组客观...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.